$Tonix Pharmaceuticals (TNXP.US)$ As of December 2024, Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL, a sublingual tablet intended for the management of fibromyalgia. If approved, it would be the first new fibromyalgia treatment in over 15 years.  Currently, the FDA has approved three medications for fibromyalgia: 1. Lyrica® (pregabalin): Approved in 2007. 2. Cymbalta® (duloxetine): Approved in 2008. 3. Savella®...
As of December 2024, Tonix Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL, a sublingual tablet intended for the management of fibromyalgia. If approved, it would be the first new fibromyalgia treatment in over 15 years. 
Currently, the FDA has approved three medications for fibromyalgia:
1. Lyrica® (pregabalin): Approved in 2007.
2. Cymbalta® (duloxetine): Approved in 2008.
3. Savella®...
👀
No comment yet